Enfuvirtide 99.81%

36-Amino Acid Synthetic Peptide Targeting gp41-Mediated Membrane Fusion

Enfuvirtide (also known as T20 or DP178) is a synthetic 36-amino acid peptide that acts as a potent HIV-1 fusion inhibitor, specifically targeting the gp41 subunit of the viral envelope glycoprotein. By binding to the heptad repeat region of gp41, Enfuvirtide blocks the formation of the fusion pore between the viral and host cell membranes, thereby preventing HIV-1 entry into CD4+ cells.

Enfuvirtide is typically used as a salvage therapy in patients infected with multi-drug resistant HIV-1 and has shown strong antiviral synergy when combined with other antiretroviral agents.

Key Features & Benefits

• ✅ Mechanism of Action – Inhibits HIV-1 entry by binding to the gp41 transmembrane protein
• ✅ IC₅₀: 23 ± 6 nM – Potent inhibition of HIV-1 membrane fusion in cell-cell fusion assays
• ✅ Combination Therapy Compatible – Enhances antiviral effects when combined with AZT, Efavirenz, or Indinavir
• ✅ Synthetic Peptide (Acetate Salt) – Manufactured with acetylated N-terminus and amidated C-terminus for increased stability
• ✅ Useful in HIV Resistance Research – Evaluates efficacy in patients with multi-drug resistance
• ✅ Cell-Based Assay Validated – Demonstrates inhibition of HIV p24 antigen and Gag gene expression in macrophages

Product Specifications

Mechanism of Action

Enfuvirtide binds to the gp41 heptad repeat region of HIV-1, preventing conformational changes required for membrane fusion. This inhibits viral entry into host cells, effectively blocking the initial stage of the viral life cycle.

In Vitro Studies

• Cell Fusion Assay: IC₅₀ = 23 ± 6 nM
• Macrophage Model: Reduces expression of HIV p24 antigen and Gag gene
• Combination Therapy: Synergistic antiviral effects when used with AZT, Efavirenz, Indinavir, or IFN-λs

Biological Effects

• Downregulates HIV-1 replication markers (e.g., p24 antigen)
• Prevents gp41-mediated fusion pore formation
• Effective against wild-type and drug-resistant HIV-1 strains
• Enhances antiviral activity of multiple drug classes

Related Antibodies (for research use)

• CD4 Antibody
• TARBP2 Antibody
• Tat SF1 Antibody
• SV40 T Antigen Antibody

Applications

🧬 HIV Entry Inhibition Studies – Analyze virus-cell fusion mechanisms

🔬 Antiviral Screening Models – Benchmark compound for fusion inhibitor class

💊 Resistance Research – Evaluate efficacy in multi-drug resistant HIV strains

🧪 Combination Antiretroviral Therapy Research – Test synergy with NRTIs, NNRTIs, PIs

🧫 Macrophage Infection Models – Study HIV latency, suppression, and immune response

Enfuvirtide (T20; DP178) remains a critical tool in HIV research, especially for investigating viral entry inhibition and drug resistance mechanisms. Its potent activity, validated assay results, and synthetic stability make it an essential component of HIV drug discovery, fusion inhibition, and immunopathology research platforms.